[go: up one dir, main page]

US3624097A - N-pyridine 5-aminooxazoles - Google Patents

N-pyridine 5-aminooxazoles Download PDF

Info

Publication number
US3624097A
US3624097A US843762A US3624097DA US3624097A US 3624097 A US3624097 A US 3624097A US 843762 A US843762 A US 843762A US 3624097D A US3624097D A US 3624097DA US 3624097 A US3624097 A US 3624097A
Authority
US
United States
Prior art keywords
phenyl
methyl
calcd
anal
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US843762A
Inventor
Maximilian Von Strandtmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of US3624097A publication Critical patent/US3624097A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Definitions

  • N-PYRIDINE S-AMINOOXAZOLES ABSTRACT The present invention is concerned with com- 4 Claims, No Drawings pounds of formula 52 0.5. CI 260/296 R,
  • R is heteroaryl and R is lower alkyl, aryl, aralkyl, or heteroaryl.
  • heteroaryl encompasses the monocyclic and bicyclic hetero aromatic compounds having at least one hetero atom in the ring which maybe either nitrogen, oxygen or sulfur.
  • Representative heteroaryl radicals falling within this definition are, for example, pyridine, quinoline, pyrrole, indole, thiophene, benzimidazole, tetrazole, pyrymidine and the like.
  • ary1 denotes an aromatic radical, preferably of six to carbon atoms, such as for example, phenyl, tolyl and the like.
  • aralkyl encompasses lower alkyl groups in which an aryl group as defined above is substituted for a hydrogen atom, such as for example, benzyl, phenethyl and the like.
  • lower alkyl as'used herein includes lower aliphatic hydrocarbons having one to five carbon atoms arranged in a straight carbon chain.
  • the compounds of this invention are useful in cases where a reduction in skeletal muscle spasm is indicated.
  • a reduction in body tone lasting for 24 hours.
  • the motor activity and temperature are also decreased for a period of about 3 to 6 hours.
  • a dose range from 100 to 500 mg./kg. is recommended to produce the desired reduction in motor activity.
  • This dosage regimen may, of course, be varied according to body weight, sex, age, species of the mammal being treated as well as the severity of the condition being treated, by methods well known to the healing an.
  • these compounds are formulated with such standard phannaceutical carriers, such as lactose, mannitol, dicalcium phosphate into dosage forms such as tablets, capsules, and the like. They can also be combined with parenterally acceptable vehicles such as sesame oil, arachis oil and the like to form dosage forms suitable for parenteral injectlon.
  • standard phannaceutical carriers such as lactose, mannitol, dicalcium phosphate into dosage forms such as tablets, capsules, and the like.
  • parenterally acceptable vehicles such as sesame oil, arachis oil and the like to form dosage forms suitable for parenteral injectlon.
  • compounds of type 1 are prepared by acylation of heteroarylamines of type 111 with azlactones of type I1 followed by cyclodehydration of the intermediate compounds of type IV.
  • the foregoing reaction is illustrated by the following schematic diagram:
  • the product is recrystallized g. of 2-pheynl-5-oxazolone and 50 ml. of THF.
  • the product is from absolute EtOH. M.P. 218219;yie1d: 1.7 g. (81%). recrystallized from acetonitrile. M.P. 193195; yield: 2.3 g.
  • EXAMPLE 12 65 s NH-C-CH NH-C NHCCHry "Q l 1 0 7 CH1 W N N 1 lMethylindol-Z-yl)carbamoyllmethyl lbenzamide N-[(2-Thiazolylcarbamoy1)methyllbenzamide ls prepared in the same manner as N-[(2-indolyl carls prepared in the same manner as N-[(2-pyridyl carbamoy1)methyl]benzamide, using 1.1 g. 1-methyl-2-amino inbamoyl)methyl]benzamide using 1 g. of 2-aminothiazole, 1.6
  • the product is azolynammolpyndme 10 Nuzbenz'mldazolylcar' recrystallized from 95% ethanol. M.P. 23 l232; yield: 1.2 g. bamoyl)methyl]benzamide, and 200 gm. PPE. The product is (62%) recrystallized from 95% ethanol. M.P. 238-239; yield: 7.1 g. AnaL Calcd for CHHmNaOCj; C, 139; H, 37 N, 1547;
  • a compound according to claim 1 which is 2-[(phenyl-5- oxazolyl)amino]pyridine.
  • a compound according to claim 1 which is 5-chloro-2-l (2pheny1-5-oxazolyl)amino]pyridine.
  • a compound according to claim 1 which is 3-[(2-phenyl- 5-oxazolyl)amino]pyridine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is concerned with compounds of formula I:

wherein R1 is heteroaryl and R2 is alkyl, aryl, or heteroaryl. Compounds of this invention exhibit central nervous system depressant properties.

Description

[muted States Patent [1113524397 72] inventor Maximilian Von Strandtmann [56] References Cited I A I N 3523 "4- UNITED STATES PATENTS pp o. 7 Filed J y 22,1969 $317,553 5/l967 Crowther et al. ..6()/3()7 [45] Patented Nov. 30, 1971 Primary ExaminerAlan L. Rotman [73] Assignee Warner-Lambert Company Attorneys-Albert H. Graddis, Henry E. Millson, Jr.. Frank S.
M ri Plain NJ, Chow. Neil D. Edwards and Anne M. Kelly [54] N-PYRIDINE S-AMINOOXAZOLES ABSTRACT: The present invention is concerned with com- 4 Claims, No Drawings pounds of formula 52 0.5. CI 260/296 R,
260/256.4 R, 260/287 R, 260/288 R, 260/295 AM, 260/295.5 A, 260/304, 260/306.8 R, 260/307 0 N R, 260/308 R, 260/309.2, 260/558 R, 260/326.l4,
424/263, 424/258, 424/272 I wherein R l is heteroaryl and R is alkyl, aryl, or heteroaryl. 307 Compounds of this invention exhibit central nervous system depressant properties N-PYRlDlNE S-AMINOOXAZOLES The present invention relates to N-heteroaryl S-amino-oxazoles having the following structural formula:
I l I wherein R is heteroaryl and R is lower alkyl, aryl, aralkyl, or heteroaryl.
In the above definitions for R and R the term heteroaryl" encompasses the monocyclic and bicyclic hetero aromatic compounds having at least one hetero atom in the ring which maybe either nitrogen, oxygen or sulfur. Representative heteroaryl radicals falling within this definition are, for example, pyridine, quinoline, pyrrole, indole, thiophene, benzimidazole, tetrazole, pyrymidine and the like. The term ary1" denotes an aromatic radical, preferably of six to carbon atoms, such as for example, phenyl, tolyl and the like. The term aralkyl" encompasses lower alkyl groups in which an aryl group as defined above is substituted for a hydrogen atom, such as for example, benzyl, phenethyl and the like. The term lower alkyl as'used herein includes lower aliphatic hydrocarbons having one to five carbon atoms arranged in a straight carbon chain.
The compounds of this invention are useful in cases where a reduction in skeletal muscle spasm is indicated. For example, at a dose of 200 mg./kg. intraperitoneally in laboratory animals, such as rats, the compounds of this invention produce a reduction in body tone lasting for 24 hours. Simultaneously, the motor activity and temperature are also decreased for a period of about 3 to 6 hours. Generally speaking, a dose range from 100 to 500 mg./kg. is recommended to produce the desired reduction in motor activity. This dosage regimen may, of course, be varied according to body weight, sex, age, species of the mammal being treated as well as the severity of the condition being treated, by methods well known to the healing an.
In order to use these compounds, they are formulated with such standard phannaceutical carriers, such as lactose, mannitol, dicalcium phosphate into dosage forms such as tablets, capsules, and the like. They can also be combined with parenterally acceptable vehicles such as sesame oil, arachis oil and the like to form dosage forms suitable for parenteral injectlon.
According to the present invention, compounds of type 1 are prepared by acylation of heteroarylamines of type 111 with azlactones of type I1 followed by cyclodehydration of the intermediate compounds of type IV. The foregoing reaction is illustrated by the following schematic diagram:
l II III IV in which R, and R, are as previously defined.
Starting compounds III are readily available from commercial sources, for example, Aldrich Chemical Co. Azlactones of type ll were prepared by the procedure described in Organic Syntheses, Vol. 47, p. 101 (John Wiley & 'Sons, lnc., New York, N.Y., 1967):
The followingexamples are included in order further to illustrutethejnvention. 1
EXAMPLE 1 N-[(lndol-2-ylcarbamoyl)methyl]benzamide EXAMPLE 2 N-[ 2-Pyridylcarbamoyl )methyl lbenzamide A solution of 1 g. 2-aminopyridine and 1.75 g. of 2-phenyl- 5-oxazolone in 50 ml. of THF is refluxed for 9 hrs. Concentration to half the original volume and chilling on an ice bath produces crystals, which are recrystallized from ethyl acetate. M.P. 172-l74; Yield: 0.6 g. (21%).
Anal. Calcd. for c,.,n, N,o,: C, 65.87; H, 5.13; N, 16.46. Found: C, 65.85; H, 5.07; N, 16.65.
EXAMPLE 3 N-[ lH-Tetrazol-S-ylcarbamoyl)methyllbenzamide A solution of 1 g. 5-amino-1H-tetrazole, 1.6 g. 2-phenyl-5- oxazolone in 100 ml. THF is refluxed for 5 hrs. Crystals which separate out of the hot solution are filtered off, slurried twice, at 1 hour each, with THE, filtered and dried. M.P. 254256; yield: 2.3 g.
Anal. Calcd. for C H N O C, 48.78; H, 41.09; N, 34.14. Found: C, 48.56; H, 4.15; N, 34.17.
EXAMPLE 4 N-[ 2-Benzothiazo1ylcarbamoyl )methyl benzamide A solution of l g. 2-aminobenzothiazole, 1.08 g. of 2-phenyl-5-oxazolone and 50 ml. THF is refluxed for 7% hrs. The precipitate is filtered off and recrystallized from EtOH (-45O ml./gm.). M.P. 262264; yield: 1.4 g. (70%).
Anal. Calcd. for C H N O,S: C, 61.72; H, 4.21; N, 13.50; 50 m1. THF and refluxing for 6 hrs. The product is recrystal- S, 10.30. Found: C, 61.75; H, 4.31; N, 13.48; S, 10.43. lized from abs. EtOH. M.P. 202-204; yield: 1.1 g. (59.5%).
Anal. Calcd. for C,,,H,-,N O,: C, 70.34; H, 5.58; N, 13.67. EXAMPLE Found: c, 70.14; H, 5.78; N, 13.51.
EXAMPLE 9 d amt -cll,-nll-t z l0 (7 N 0 0 )NH-CCH NH-fi- N l O G N-[ 2-Benzimidazolylcarbamoyl )methyl lbenzamide A solution of 0.5 g. 2-aminobenzimidazo1 and 0.6 g. of 2- N ms'chbmpynd'z'yl)ca'ba'myllmethy'lbenzam'de pheny1-5-oxazolone in 50 ml. of THF is refluxed until a Is prepared in the same manner as N-[(2-pyridy1 carpl'oduct separates out (=30 min.). This is filtered off and bamoyl)methyl]benzamide using 1 g. 2-amino-5-chlopyridine, recrystallized from 95% EtOH. M.P. 303305; yield: 0.9 g. 1.25 g. 2-phenyl-5-0xamlone, in 50 ml. THF and refluxing for (82%). 18 hrs. The product is recrystallized from abs. ethanol. M.P.
Anal. Calcd. for c,,l-l,,N,o,: c, 65.29; H, 4.80; N, 19.04. 229 230"; yield: 1.6 g. (71.5% Found: C, 65.2; H, 4.92; N, 18.99. Anal. Calcd. for c,,ll,,N,o,cl= C, 58.04; H, 4.18; N, 14.50.
Found: C, 57.77; H, 4.16; N, 14.25. EXAMPLE 6 EXAMPLE 10 11 f NH-0-CH,-NH-4 3 O 0 ll .1
N-[( 2-Quinolylcarbamoy1)methyl]benzamide N-[(3-Pyridylcarbamoy1)methyl]benzamide ls prepared in the same manner as N-[(2-pyridy1 car- 18 prepared in the same manner as N-[(2-pyridylcarbamoyl)methyl]benzamide using 1 g. 2-aminoquinoline, 1.1 g. bamoyl)methyl]benzamide using 2 g. of 3-aminopyridine, 3.5 Z-phenyl-S-oxazolone and THF. The product is recrystallized g. of 2-pheynl-5-oxazolone and 50 ml. of THF. The product is from absolute EtOH. M.P. 218219;yie1d: 1.7 g. (81%). recrystallized from acetonitrile. M.P. 193195; yield: 2.3 g.
Anal Calcd. for c,,,ll,,N,,0,. c, 70.80; H, 4.95; N, 13.76. 43% Found: C, 70.98; H, 5.00; N, 13.95. Anal. Calcd. for C,,H,,N,0,: C, 65.87; H, 5.13; N, 16.46.
Found: C, 66.16; H, 5.22, N, 16.50. EXAMPLE 7 EXAMPLE 1 1 N 1 1 I Q NH-C-CH NHC l1 l O 0 5O N-[N-Methylphenylcarbamoyl)methyl]benzamide IS P p in Same manner as 1W y can N-[(2-Pyr1mldlnylcarbamoyl)methyllbenzamlde bamoyl)methy1]benzamide using3 g. N-methylaniline, 4.5 g. ls prepared in the same manner as N-[(2-pyridylcar- 2-phenyl-5-oxazolone in m1. THF and refluxing for 28 hrs. barnoy1)methy1]benzamide using 2 g. of 2-aminopyrimidine, The product is recrystallized from Skelly B. M.P. 84-85; 3.4 g. 2-phenyl-5-oxazolone and 50 ml. THF. The product is yield: 4.7 g. (63%). recrystallized from ethyl acetate. M.P. 219-220; yield: 0.3 g.
Anal. Calcd. for CmHmNgOgZ C, 71.62; H, 6.01; N, 10.44. (55%). Found: C, 71.70; H, 6.02; N, 10.18. Anal. Calcd. for C,;,H,,N,O C, 60.93; H, 4.72; N, 21.87.
Found: C, 60.78; H, 4.74; N, 21.87. EXAMPLE 8 EXAMPLE 12 65 s NH-C-CH NH-C NHCCHry "Q l 1 0 7 CH1 W N N 1 lMethylindol-Z-yl)carbamoyllmethyl lbenzamide N-[(2-Thiazolylcarbamoy1)methyllbenzamide ls prepared in the same manner as N-[(2-indolyl carls prepared in the same manner as N-[(2-pyridyl carbamoy1)methyl]benzamide, using 1.1 g. 1-methyl-2-amino inbamoyl)methyl]benzamide using 1 g. of 2-aminothiazole, 1.6
dole HCl 1 g. 2-phenyl-5-oxazolone, 0.5 g. sodium acetate in g. of 2-phenyl-5-oxazolone and 50 ml. THF refluxing for 4 hrs.
6 The product is recrystallized from abs. EtOH. M.P. 238239, Anal. Calcd. for C H N OS: C, 65.51; H, 3.78; N, 14.32; S, yleldz 8- 10.93. Found: C. 65.55; H, 3.89; N, 14.31; S, ll.l6.
Anal. Calcd. for C H N O S: C, 55.16; H, 4.24; N, 16.08; 5, 12.27. Found: c, 55.32; 11, 4.40; N, 16.29; s, 12.21. EXAMPLE 16 5 EXAMPLE l3 1 19114320 (L J. .1. \N NH- I =(llH 2-[ 2-Phenyl-5-oxazolyl )amine ]thiazole -l( y y l lpy Is prepared in the same manner as 2-[(phenyl-5ox- 5 g. N-[(2-pyridyl carbamoyl)methyl]benzamide is added amlYDammelPyndme 6 f" to 100 g. of PPE and stirred for hrs. The solution is poured bamoylmlethynbenzam'de and 150 "3 i Product onto 300 f ice and water with stirring and basified with recrystalllzed from abs. ethanol. M.P. 190 l9l y1eld: 3.8 g.
ammonium hydroxide. The precipitate is filtered, washed with (635%) water and is recrystallized from abs. ethanol. M.P. l69-170; 25 Anal- Calcd- CIZHQNGOS: C, 59.24; H, 3.73; N, 17.27.
yield; 1,5 (32%), Found: c, 58.95; H, 4.02; N, 17.12; s, 13.07.
Anal. Calcd. for CMHUN3O: C, 70.87; H, 4.67; N, 17.71. Found: c, 70.98; H, 4.7 1; N, 17.80. EXAMPLE EXAMPLE 14 01 N L JNHC=CH ll N 1 1 5 NH-C=CH N I I \I/ H 0 N 5-Chloro-2[(2-phenyl-5-oxazolyl)aminolpyridine 2[(Z-Phenyl-S-oxazolyl)aminelbenzimidazole 4 [S P R f sfame manner as P "y IS P p Sflme manner as -l (1 y carbamoyl)methyllbenzamide and 4.5 g. PPE. The product is azolynammolpyndme 10 Nuzbenz'mldazolylcar' recrystallized from 95% ethanol. M.P. 23 l232; yield: 1.2 g. bamoyl)methyl]benzamide, and 200 gm. PPE. The product is (62%) recrystallized from 95% ethanol. M.P. 238-239; yield: 7.1 g. AnaL Calcd for CHHmNaOCj; C, 139; H, 37 N, 1547;
(70%)- c1, 13.05. Found: c, 62.01; H, 3.72; N, 15.35;c1, 13.05.
Anal. Calcd. for C,6H12N.,O: C, 69.55; H, 4.38; N, 20.28. Found: C,69.6l;H,4.39; N, 20.57. EXAMPLE18 EXAMPLE 15 q s Nil-0:01; J N 1 /NHC===CH N 1 Y.
2-[(Phenyl-S-oxazolyl)amine]quinoline ls prepared in the same manner as 2[(phenyl-5-ox- 7Q azolyl)amine]pyridine using 3.7 g. of N-[(2-quninolyl carls prepared in the same manner as 2-[( he l-5- bamoyl)methyl]benzamide and g. of PPE. The product is azolyl)amino]pyridine using 5 g. N-[(2-benzothiazoylycarrecrystallized from ethyl acetate. M.P. l-l92: yield: 2.7 g. bamoyl)methyl]benzamide and g. of PPE. The product is recrystallized from abs. ethanol. M.P. 228 229; yield: 3 g. Anal. Calcd. for C H N O: C, 75.24; H, 4.56; N, 14.63. (60%). 1 75 FoundzC, 75.15; H,4.'56; N, 14.60.
2[(2-Phenyl-5-oxazolyl)amine]benzothiazole EXAMPLE 19 NHo=oH 3-[(2-phenyl-5-oxazoly1)aminolpyridine ls prepared in the same manner as 2-[(phenyl-5-oxazoly1)amino]pyridine using 1 g. of N-[(3-pyridyl carbamoyl)methyl]benzamide, 25 g. PPE and stirring for 72 hrs. The product is recrystallized from toluene. M.P. l48-l50; yield: 0.5 g. (49%).
Anal. Calcd. for C H N O: C, 70.87; H, 4.67; N, 17.71. Found: C, 70.89; H, 4.76; N, 17.57.
EXAMPLE 2O H o N 2-[(2-Phenyl-5-oxazolyl)amino]indole 4.5 g. of N-[(indol-2-yl carbamoyl)methyl]benzamide is stirred with 90 g. PPE for 45 hrs. The solution is poured onto ==300 ml. of ice and water with stirring and basified with ammonium hydroxide. The precipitate is filtered off and washed well with water. Yield: 3.8 g. (94%). The product is recrystallized from acetonitrile. M.P. 238240; yield: 1.6 g. (39.5%).
Anal. Calcd. for c,,H,,,N,0: C, 74.16; H, 4.73; N, 15.26.
Found: C, 74.11;H, 5.95; N, 15.05.
EXAMPLE 21 NHC:2-C1I \N/ l 1 l-Methyl-2-[(phenyl-S-oxazolyl )aminolindole R HN whereinR is pyridine or chloropyridine and R is lower alkyl or phenyl.
2. A compound according to claim 1 which is 2-[(phenyl-5- oxazolyl)amino]pyridine.
3. A compound according to claim 1 which is 5-chloro-2-l (2pheny1-5-oxazolyl)amino]pyridine.
4. A compound according to claim 1 which is 3-[(2-phenyl- 5-oxazolyl)amino]pyridine.

Claims (3)

  1. 2. A compound according to claim 1 which is 2-((phenyl-5-oxazolyl)amino)pyridine.
  2. 3. A compound according to claim 1 which is 5-chloro-2-((2-phenyl-5-oxazolyl)amino)pyridine.
  3. 4. A compound according to claim 1 which is 3-((2-phenyl-5-oxazolyl)amino)pyridine.
US843762A 1969-07-22 1969-07-22 N-pyridine 5-aminooxazoles Expired - Lifetime US3624097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84376269A 1969-07-22 1969-07-22
US15155371A 1971-06-09 1971-06-09

Publications (1)

Publication Number Publication Date
US3624097A true US3624097A (en) 1971-11-30

Family

ID=26848745

Family Applications (2)

Application Number Title Priority Date Filing Date
US843762A Expired - Lifetime US3624097A (en) 1969-07-22 1969-07-22 N-pyridine 5-aminooxazoles
US00151553A Expired - Lifetime US3717642A (en) 1969-07-22 1971-06-09 N quinoline 5 aminooxazoles

Family Applications After (1)

Application Number Title Priority Date Filing Date
US00151553A Expired - Lifetime US3717642A (en) 1969-07-22 1971-06-09 N quinoline 5 aminooxazoles

Country Status (1)

Country Link
US (2) US3624097A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567887A1 (en) * 1984-07-19 1986-01-24 Rhone Poulenc Sante NEW SUBSTITUTED AMIDES, THEIR PREPARATION AND THE MEDICINES THAT CONTAIN THEM
WO1991017150A1 (en) * 1990-04-27 1991-11-14 Warner-Lambert Company Tetrazole urea and thiourea acat inhibitors
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148841A1 (en) * 2004-02-26 2006-07-06 Lundeen James E Pharmaceutical composition comprising combination of non-alkaloid and alkaloid-based component for treating skeletal muscle spasm
WO2019152437A1 (en) 2018-01-30 2019-08-08 Foghorn Therapeutics Inc. Compounds and uses thereof
AR121226A1 (en) 2020-01-29 2022-04-27 Foghorn Therapeutics Inc COMPOUNDS AND USES OF THESE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317553A (en) * 1963-07-19 1967-05-02 Ici Ltd 5-aroxymethyloxazolidines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2362337A (en) * 1942-07-31 1944-11-07 American Cyanamid Co Process of making 2-aminooxazole
US2494083A (en) * 1945-04-17 1950-01-10 Wyeth Corp Disubstituted glycyl derivatives of amino quinolines
US2456911A (en) * 1945-05-04 1948-12-21 Wyeth Corp Disubstituted acetamidyl derivatives of amino quinolines
US3054794A (en) * 1958-01-17 1962-09-18 Us Vitamin Pharm Corp Process for preparing 3-(aminoalkyl)-oxazolidine-2, 4-diones
US3376307A (en) * 1964-10-29 1968-04-02 Nepera Chemical Co Inc Amino esters of (2, 3 or 4) pyridyl carbamic acid
US3401173A (en) * 1966-04-05 1968-09-10 Smith Kline French Lab Heterocyclic acylaminobenzimidazoles
US3511851A (en) * 1967-06-12 1970-05-12 Du Pont Heterocyclic amino-oxazolines
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317553A (en) * 1963-07-19 1967-05-02 Ici Ltd 5-aroxymethyloxazolidines

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567887A1 (en) * 1984-07-19 1986-01-24 Rhone Poulenc Sante NEW SUBSTITUTED AMIDES, THEIR PREPARATION AND THE MEDICINES THAT CONTAIN THEM
EP0172083A1 (en) * 1984-07-19 1986-02-19 Rhone-Poulenc Sante Substituted amides, their preparation and pharmaceutical compositions containing them
US4642308A (en) * 1984-07-19 1987-02-10 Rhone-Poulenc Sante N-(1,8-naphthyridin-2-yl) amides and their pharmaceutical use
WO1991017150A1 (en) * 1990-04-27 1991-11-14 Warner-Lambert Company Tetrazole urea and thiourea acat inhibitors
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
US5948804A (en) * 1996-02-29 1999-09-07 Synaptic Pharmaceutical Corporation Substituted indoles and uses thereof
US6040451A (en) * 1996-02-29 2000-03-21 Synaptic Pharmaceutical Corporation Substituted indoles and uses thereof
US6159998A (en) * 1996-02-29 2000-12-12 Synaptic Pharmaceutical Corporation Substituted indoles and uses thereof
US6303643B1 (en) 1996-02-29 2001-10-16 Synaptic Pharmaceutical Corporation Substituted indoles and uses thereof
US6498177B2 (en) 1996-02-29 2002-12-24 Synaptic Pharmaceutical Corporation Indole and benzothiazole derivatives
US6723741B2 (en) 1996-02-29 2004-04-20 Synaptic Pharmaceutical Corporation Benzimidazoles and benzothiazoles and uses thereof

Also Published As

Publication number Publication date
US3717642A (en) 1973-02-20

Similar Documents

Publication Publication Date Title
US3813400A (en) Derivatives of 3-amino-1,2,4-triazoles
ES8600299A1 (en) Diuretic 6-vinyl-furo-(3,4-c)-pyridine derivatives
US3624097A (en) N-pyridine 5-aminooxazoles
US2755285A (en) I-xsubstituted
CA1093081A (en) Process for the production of aryl ureas
US3375257A (en) N-(acyl amino substituted pyridyl)-n-(phenyl or pyridyl)amines
US3450694A (en) Substituted benzoxazepines and benzothiazepines
Fitt et al. Lithiation of N, N-dimethyl-3-(phenylthio)-2-propenylamine
US2835668A (en) Pyridylethylated benzoxazinediones and process for preparation
Roblin Jr et al. Chemotherapy. I. Substituted Sulfanilamidopyridines1
US2489355A (en) Benzotriazines
US3780047A (en) Derivatives of pyrazolo(3',4'-2,3)pyrido(4,5-e)b-benzo-1,5-diazepines
US2987518A (en) Certain 1h [4, 5-c]-imidazopyridines
US3299081A (en) Chemical processes for preparing nu-substituted amidines
SU436495A3 (en) Method for producing benzodiazepine derivatives
US3798220A (en) Process for preparing 4-hydroxy 5-substituted pyrimidines and products obtained
Shishoo et al. A facile synthesis of 3‐amino‐5‐substitutedaminoisothiazole‐4‐carboxylic acid derivatives
US3236853A (en) Triazolidines and process for preparing them
US3932409A (en) Urethane derivatives of 2-phenyl-4(3H)-quinazolones
US3225062A (en) Process for 1,2-dithiole-3-thiones
US2949463A (en) Certain 1, 3-diphenyl-2-thioparabanic acids
US3062813A (en) Novel synthesis of sulfonamides
Alkorta et al. Synthesis, hydrolysis reactions and conformational study of 2-substituted 3, 5-diamino-4-nitroso-2 H-1, 2, 6-thiadiazine 1, 1-dioxides
US2949459A (en) Di-substituted phenyl-z-tffloureas
US2647123A (en) Nu-(2-pyridyl) 2-chloro-3-amino-1, 4-naphthoquinones